N-in-1 dosing pharmacokinetics in drug discovery: Experience, theoretical and practical considerations

被引:32
作者
He, Kan [1 ]
Qian, Mingxin [1 ]
Wong, Harvey [1 ]
Bai, Stephen A. [1 ]
He, Bing [1 ]
Brogdon, Bernice [1 ]
Grace, James E. [1 ]
Xin, Baomin [1 ]
Wu, Jingtao [1 ]
Ren, Shelly X. [1 ]
Zeng, Hang [1 ]
Deng, Yuzhong [1 ]
Graden, Danielle M. [1 ]
Olah, Timothy V. [1 ]
Unger, Steve E. [1 ]
Luettgen, Joseph M. [1 ]
Knabb, Robert M. [1 ]
Pinto, Donald J. [1 ]
Lam, Patrick Y. S. [1 ]
Duan, James [1 ]
Wexler, Ruth R. [1 ]
Decicco, Carl P. [1 ]
Christ, David D. [1 ]
Grossman, Scott J. [1 ]
机构
[1] Bristol Myers Squibb Co, Dept Pharmaceut Candidate Optimizat, Princeton, NJ 08543 USA
关键词
N-in-1; dosing; cassette doing; pharmacokinetics; drug discovery; drug-drug interactions;
D O I
10.1002/jps.21196
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug-drug interactions this procedure is still controversial. This study was to retrospectively evaluate the N-in-1 dosing approach in drug discovery with an emphasis on the potential for drug-drug interactions. The systemic clearance, volume of distribution, oral bioavailability, and renal excretion of the 31 lead compounds in rats, dogs or chimpanzees were significantly correlated between the N-in-1 dosing and discrete studies with r values of 0.69, 0.91, 0.53, and 0.83 (p < 0.005 for all), respectively. PK parameters for 11 quality control compounds which were involved in 194 N-in-1 studies for screening approximately 1000 compounds had coefficient of variations of less than 70%. The intrinsic microsomal clearances generated from the N-in-1 and discrete incubations were nearly identical (r = 0.97, p < 0.0001). The intrinsic clearances of quality control compound from the N-in-1 incubations were consistent with its discrete CLint estimate (cv: 5.4%). Therefore, N-in-1 dosing is a useful approach in drug discovery to quickly obtain initial PK estimates. Potential drug-drug interactions that result in confounding PK estimates do not occur as frequently as expected. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:2568 / 2580
页数:13
相关论文
共 35 条
[1]  
Ackermann Bradley L., 2002, Current Topics in Medicinal Chemistry, V2, P53, DOI 10.2174/1568026023394605
[2]  
Adkison K K, 1998, Pharm Biotechnol, V11, P423
[3]  
Allen MC, 1998, PHARMACEUT RES, V15, P93
[4]   Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry [J].
Balani, SK ;
Nagaraja, NV ;
Qian, MG ;
Costa, AO ;
Daniels, JS ;
Yang, H ;
Shimoga, PR ;
Wu, JT ;
Gan, LS ;
Lee, FW ;
Miwa, GT .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (03) :384-388
[5]  
Beaudry F, 1998, RAPID COMMUN MASS SP, V12, P1216, DOI 10.1002/(SICI)1097-0231(19980915)12:17<1216::AID-RCM304>3.0.CO
[6]  
2-O
[7]   Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput [J].
Berman, J ;
Halm, K ;
Adkison, K ;
Shaffer, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) :827-829
[8]  
Christ DD, 2001, DRUG METAB DISPOS, V29, P935
[9]  
Copeland RA, 2000, J PHARM SCI, V89, P1000, DOI 10.1002/1520-6017(200008)89:8<1000::AID-JPS4>3.0.CO
[10]  
2-1